Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Multi-Regional Trials Have yet to Become the Norm
BioCentury’s website outlines a comprehensive cookie policy that categorises cookies into strictly necessary, functional, marketing, advertising, and analytics types. Strictly necessary cookies are always active and essential for authentication and site navigation, while functional cookies enable enhanced personalization. Marketing and advertising cookies help tailor product offers and track ad performance, though they do not store personal identifiers. Analytics cookies, both internal and third‑party, collect usage data to improve services and detect misuse, even when users block other cookies.
Robert F. Kennedy Jr. Defends Spending Cuts to Health Agencies
President Trump’s FY 2027 budget proposes a $111.1 billion allocation for HHS, a 12.5% cut from the current year that would slash NIH research grants and programs for women and children. HHS Secretary Robert F. Kennedy Jr. defended the reductions, arguing that many...
Urine Biomarker May Predict Bladder Cancer Treatment Response, Study Finds
Stanford researchers have created a urine‑based liquid biopsy that detects tumor DNA to predict which non‑muscle invasive bladder cancer (NMIBC) patients will benefit from BCG immunotherapy. In a Cell‑published study, patients with detectable tumor DNA after BCG had a high...
Noxopharm SOF-SKN Data Shows Prolonged Skin Retention with Minimal Systemic Absorption
Australian biotech Noxopharm announced preclinical pharmacokinetic results for its SOF‑SKN candidate, showing a skin half‑life of roughly 3.5 days with negligible systemic exposure. The active moiety, SOF‑16, demonstrated consistent dermal concentrations across normal and disease‑like skin and remained confined to...
FDA Clears Merck's First Once‑Daily Oral HIV Pill
The U.S. Food and Drug Administration approved Merck's once‑daily oral HIV pill, the first daily regimen from a major pharmaceutical firm in recent years. The decision positions Merck to compete more directly in the HIV market and could reshape treatment...
Durvalumab Plus FLOT Improves Resectable Gastric Cancer Outcomes
EFS in MATTERHORN: A Ph3 RCT of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin & docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC) - @YJanjigianMD et al. #ASCO25 LBA5 https://t.co/lW8KUtXdB3 #NCT04592913 #stcsm #esocsm
CtDNA‑guided Cam
Camizestrant + CDK4/6i for the Tx of emergent ESR1 mutations during 1L endocrine-based therapy & ahead of disease progression in Pts w/ HR+/HER2– advanced breast cancer (ABC): ...ctDNA-guided SERENA-6 trial - Turner et al. #ASCO25 LBA4 https://t.co/9jFfuGd1IS #NCT04964934 #bcsm
NIH‑Backed AI Model Beats Baselines in Rare Lung Disease Detection
A National Institutes of Health‑funded team unveiled the WEakly Supervised Transformer (WEST) algorithm, which outperformed all baseline models in identifying two rare lung diseases from electronic health records. The breakthrough could shorten diagnostic delays for patients with pulmonary hypertension and...
Rusfertide Shows Efficacy in Phase 3 PV Trial
Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV) - @KuykendallMd et al. #ASCO25 LBA3 https://t.co/XID3tkj6Sk #NCT05210790 #mpnsm
Adjuvant Nivolumab Boosts Outcomes in High‑Risk HNSCC
NIVOPOSTOP (GORTEC 2018-01): Ph3 RCT of adjuvant nivolumab added to radio-chemotherapy in Pts w/ resected head & neck squamous cell carcinoma at high risk of relapse - Bourhis et al. #ASCO25 LBA2 https://t.co/Uxh4JhZyDE #NCT03576417 #hncsm #ImmunoOnc
NIH-Funded AI Model Predicts Cancer Survival From Single-Cell Tumor Data
Researchers at Oregon Health & Science University, funded by the NIH, unveiled scSurvival, an AI model that predicts cancer patient survival from single‑cell tumor data. The tool was evaluated on clinical datasets from more than 150 melanoma and liver cancer...
Atezolizumab Boosts Adjuvant Therapy for dMMR Colon
RCT of standard chemotherapy +/- atezolizumab as adjuvant therapy for Pts w/ stage III deficient DNA mismatch repair (dMMR) colon cancer (@ALLIANCE_org A021502; ATOMIC) - @FASinicropeMD et al. #ASCO25 LBA1 https://t.co/cGalNPlxMe #NCT02912559 #crcsm
First Tumor NGS Usage Varies Across Top Five Cancers
Utilization and timing of first tumor next-generation sequencing testing (NGS) in Pts w/ 5 most common cancers in the USA - @chadihcmd et al. @huntsmancancer #ASCO25 Abstract 11014 https://t.co/lWefncnTb2 #PrecisionMedicine #hemonc #bcsm #crcsm #lcsm #pancsm #pcsm https://t.co/oIX8QTRD8x
Dr. Jonathan M. Green Selected as CEO of the NIH Clinical Center
Dr. Jonathan M. Green, M.D., MBA, has been appointed CEO of the NIH Clinical Center, the world’s largest hospital dedicated to clinical research, effective May 17, 2026. He will oversee a 200‑bed, 870,000‑square‑foot facility with an annual operating budget of roughly $700 million....
Lakeridge and Partners Go Live on Sectra Cloud
Lakeridge Health and six regional partners have launched Sectra One Cloud, a cloud‑based diagnostic imaging platform that unifies access to X‑rays, CT scans and MRIs across 13 sites in Ontario’s Central East Region. The system handles roughly one million imaging...
Tava Health Secures $40 Million Series C to Scale AI‑Powered Behavioral Health Platform
Tava Health announced a $40 million Series C round led by Centana Growth Partners, bringing its total funding to $73 million since 2020. The capital will fund three new AI‑enabled products—Overture, Symphony, and Tempo—and deepen support for clinicians, clinics, and health plans....
AGE-WELL Creates AI & Aging Council
AGE-WELL has launched an AI & Aging Council to steer the responsible development and governance of artificial intelligence for Canada’s aging population. The council brings together leaders from industry, academia, care organizations, older adults and caregivers to advise on AI...
VHA Launches AI-Driven Client Portal
VHA Home HealthCare has added the Evha AI Assistant to its myVHA client portal, offering real‑time navigation and service information. The tool answers questions about portal use, VHA programs, and caregiver support while adhering to strict AI governance. VHA’s leadership...
FDA Issues Draft Guidance to Fast‑Track Ultra‑Rare, Individualized Therapies
The U.S. Food and Drug Administration released a draft guidance on Feb. 23, 2026 outlining a “plausible mechanism framework” for individualized therapies targeting ultra‑rare genetic diseases. The roadmap aims to replace traditional randomized trials with mechanistic data, accelerating approval pathways for treatments...
Michael Dell Funds ‘AI Native’ Medical Centre with $750M
Billionaires Michael and Susan Dell have pledged a $750 million gift to the University of Texas at Austin to create the UT Dell Medical Center, slated to open in 2030 as the nation’s first “AI‑native” hospital. The donation, the largest ever...
Barrie’s RVH Acquires EBUS for Lung Exams
Royal Victoria Regional Health Centre in Barrie has launched Endobronchial Ultrasound (EBUS) with Rapid On‑Site Evaluation (ROSE), a minimally invasive day procedure for lung and lymph‑node assessment. The addition expands the hospital’s endoscopy suite with a fourth procedure room, boosting...
Problems with Robotic Knee Replacement: Study
A population‑based study from Sunnybrook examined 75,000 total knee arthroplasties in Ontario between 2019 and 2023, including 1,613 robotic‑assisted procedures. The analysis found a major complication rate of 2.0% for robotic‑assisted surgery versus 1.0% for conventional techniques. Robotic cases also...
Healthcare Services Group Inc (HCSG) Q1 2026 Earnings Call Transcript
Healthcare Services Group reported Q1 revenue of $407.8 million and net income of $24.7 million, delivering earnings of $0.33 per share. Direct costs fell to 82.6% of revenue, improving segment margins to 13.1% and 10.4% while SG&A stayed under 10%. The board...
Boston Scientific Corp (BSX) Q1 2026 Earnings Call Transcript
Boston Scientific reported $20.74 billion in full‑year 2025 operational revenue, a 19% increase, and adjusted EPS of $3.06, up 22% versus guidance. Organic growth hit 15.8% for the year, driven by double‑digit expansion in electrophysiology (73% organic) and the WATCHMAN franchise...
Divalent siRNA Clinical Trial Is Now Recruiting
A first‑in‑human trial of a divalent PrP‑siRNA (2439‑s4) is now enrolling 15 symptomatic prion disease participants. The FDA‑cleared IND permits a single‑ascending‑dose study, testing 50 mg, 100 mg and 200 mg levels to assess safety and target engagement. The trial includes an optional...
Voters Ban AHF's Taxpayer-Funded Ballot Initiative Abuse
For about a decade, the AIDS Healthcare Foundation used many millions of taxpayer dollars to fund a series of ridiculous ballot initiatives reflecting their CEO's personal beefs before voters in 2024 made this illegal. You think you know how weird...
#AAN26: Roche’s Multiple Sclerosis Pill Delays Relapse, but Liver Toxicity Could Need Monitoring
Roche’s experimental multiple sclerosis pill fenebrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, more than doubled the relapse‑free interval compared with Sanofi’s oral therapy Aubagio in a late‑stage trial. The Phase 3 data showed roughly 68% of patients remained relapse‑free at...
STAT+: With Successful Trials, Roche Takes Its MS Drug to Regulators, but Safety Questions Loom
Roche presented data on its experimental multiple‑sclerosis drug fenebrutinib, which showed efficacy in three late‑stage trials by cutting relapse rates and slowing disability progression. The Swiss firm is now seeking regulatory approval, but analysts highlight liver‑safety signals and two drug‑related...
Nurix's NRX-0305 Shows
New degrader from Nurix looks interesting: NRX-0305 demonstrated antitumour activity across a wide range of Class 1 BRAF inhibitor-resistant and Class 2/3 mutant PDX models #aacr26 https://t.co/0UGF5Od2Cp
CMS Orders Medicaid Audits in Data-Driven Fraud Crackdown
The Centers for Medicare and Medicaid Services (CMS) ordered all 50 states to submit a provider revalidation plan within 30 days, aiming to verify Medicaid providers and target high‑risk areas for waste, fraud and abuse. Administrator Mehmet Oz emphasized data‑driven...
Psychedelics Could Revolutionize Psychiatry Like Microscopes Transformed Biology
“Psychedelics, used responsibly and with proper caution, would be for psychiatry what the microscope is for biology and medicine." – Stanislav Grof
Insufficient Contingency Funds Risk New Hospital Programme Delays, MPs Warn
The Public Accounts Committee warned that the UK government’s £60 billion (≈$76 billion) New Hospital Programme lacks sufficient contingency funding, allocating only 3% of the £8.9 billion (≈$11.3 billion) budget for projects through 2029/30. This shortfall could trigger cost overruns and push back the...
‘Smart Fabric’ Turns Sweat Into Real-Time Health Data
Researchers at South Korea’s DGIST have created a wearable smart fabric that analyzes sweat chemistry in real time without any electronic components. The textile incorporates a flexible semiconductor fiber within a biodegradable, porous matrix that wicks sweat into the material...
First Personalized CAR‑T Shows Mobility Gains in Stiff Person Syndrome
$KYTX Kyverna Therapeutics cell therapy improves mobility in patients with stiff person syndrome. If cleared, the medicine would be first personalized CAR-T therapy for an autoimmune disease https://t.co/B28Zp9IA2O
STAT+: Kyverna Therapeutics Plans to Submit Cell Therapy for Stiff Person Syndrome for FDA Approval
Kyverna Therapeutics announced that its personalized CAR‑T cell therapy improved mobility and reduced disability in patients with stiff person syndrome, a rare autoimmune neurological disorder. The company plans to file an FDA submission by mid‑2026, which would make it the...
Daraxonrasib Monotherapy
Eileen O’Reilly’s daraxonrasib monoTx data in 1L PDAC - poster below to save y’all fighting through rows of people to get a view #aacr26 https://t.co/z4yW2apCBf
Optum CEO: Value-Based Care Drives Sharp Drop in Nursing Home Admissions
Optum’s value‑based care (VBC) program is driving a steep decline in skilled nursing facility (SNF) admissions, with a reported 35% drop in the first month compared to a year earlier. The company attributes the reduction to more data‑driven clinical management,...
Avacta Unveils FAP‑cleavable Dual TOPO‑Ii/DDR‑i Payload
Intriguing #AACR26 poster from Avacta w/ CSO Francis Wilson presenting on their dual payload tech. The idea is to release TOPO-Ii + DDRi via FAP cleavage https://t.co/UMeB8y8KaC
Examining Racial Disparities in Health Care
Recent studies highlight pervasive racial disparities in Canadian health care, showing BIPOC patients experience longer emergency department wait times, delayed non‑urgent appointments, and frequent discrimination from providers. The article cites that over a quarter of Indigenous Canadians wait two weeks...
The Great Ozempic Experiment
GLP‑1 medications such as Ozempic and Zepbound have moved beyond weight‑loss to treat a spectrum of conditions, from traumatic brain injury to long Covid and addiction. An interactive New York Times report highlights that roughly one in eight Americans have tried these...
Benzodiazepine Withdrawal Is Mitochondrial Dysfunction
Benzodiazepines, widely prescribed for anxiety and insomnia, act as whole‑body drugs that target mitochondrial receptors, not just brain GABA pathways. Both chronic use and abrupt cessation can trigger mitochondrial dysfunction, linking the drugs to a roughly 60% increase in mortality...
Walz: ‘Next Democratic President Better Figure Out a Way to Get Universal Health Care’
Minnesota Governor Tim Walz told MS NOW’s “The Weeknight” that the next Democratic president must find a way to enact universal health care, warning that failure would leave the party stuck in a status‑quo cycle. He framed the push as a...
Older Adults Often Don’t Need Colonoscopies or Levothyroxine
Many older adults do not need screening colonoscopies or the low thyroid drug levothyroxine: https://t.co/f2C1WrrrN7 #coloncancer #healthcare #seniors #olderadults
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
Zymeworks unveiled Phase 1 data for ZW191, a folate‑receptor‑α‑targeting antibody‑drug conjugate, at the AACR 2026 meeting. In platinum‑resistant ovarian cancer the drug showed a confirmed objective response rate of 61% at 6.4‑9.6 mg/kg, with a median progression‑free survival of 7.6 months and responses...
U.S. MILITARY ENDS 72-YEAR MANDATORY FLU SHOT POLICY
On April 20, 2026, the Secretary of War issued a memorandum ending the U.S. military’s 72‑year mandatory influenza‑vaccination policy, making the flu shot voluntary for active‑duty, reserve, and Department of War civilian personnel. The requirement, first introduced in 1945 during...
ARVN KRAS G12D Preclinical Shows Weak Tumor Inhibition
In the battle of the inhibitors vs glues vs degraders, this one (KRAS G12D preclinical) from ARVN doesn't look too encouraging with little TGI #aacr26 https://t.co/Ng9UWTQcsv
UnitedHealth Group Investing Billions in AI
UnitedHealth Group announced a $1.5 billion investment in artificial intelligence to modernize its internal operations and launch commercial AI products. The spend targets member and patient engagement tools, workflow automation, and productivity gains across its health‑care and insurance divisions. In Q1...
First Set of Research Teams Announced in Effort to Transform Behavioral Health
The Advanced Research Projects Agency for Health (ARPA‑H) unveiled the first cohort of research teams under its EVIDENT initiative, allocating up to $139.4 million to accelerate rapid‑acting behavioral‑health therapies. At least $50 million is reserved to match state investments in psychedelic studies...
AI Integrates Omics and Lifestyle to Forecast Health Outcomes
A multimodal AI agentic model that integrates electronic medical records, lifestyle, layers of biologic omics data to predict health outcomes and, with perturbations, "what if" scenarios a person improved lifestyle or took a medication @Cell_Metabolism https://t.co/qgVomjkipS https://t.co/JDaeYv0JGu
Compass Therapeutics, Inc. (CMPX) Up 200% Year-on-Year
Compass Therapeutics (CMPX) has delivered a spectacular rally, climbing 237% over the past year and gaining 16% year‑to‑date. Analyst John Newman of Cannaccord Genuity reaffirmed a Buy rating with a $13 price target on April 7. CEO Thomas Schuetz highlighted that the...